The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications
Open accessAbstract
Purpose: 5-Hydroxytryptamine-3 receptor antagonists (5-HT 3 antagonists) are effective for preventing acute chemotherapy-induced emesis but the benefits of continuing administration of these agents beyond 24 hours after chemotherapy (delayed emesis) remain unclear. The purpose of this study was to provide estimates of clinical efficacy and drug acquisition cost associated with administering 5-HT 3 antagonists beyond 24 hours, as monotherapy or as added to dexamethasone. Methods: This analysis is based on the Cancer Care Ontario Practice Guidelines Initiative meta-analysis of the efficacy of 5-HT 3 antagonists. Results from the clinical trials covered in that meta-analysis were reanalyzed to provide estimates of absolute risk reductions (ARR) and numbers needed to treat (NNT) for 5-HT 3 antagonists, as monotherapy or as adjunct treatment. Numbers of 5-HT 3 antagonist unit doses per successfully treated patient were also calculated. Results: Five studies (comprising 1,716 assessable patients) compared a 5-HT 3 antagonist with placebo; five studies (2,240 patients) compared a combination of a 5-HT 3 antagonist and dexamethasone with dexamethasone monotherapy. ARR for monotherapy was only 8.2% (95% CI, 3.0% to 13.4%). On average, 74 5-HT 3 antagonist doses must be administered to 12 patients (NNT, 12.2; 95% CI, 7.5 to 33.4) not receiving dexamethasone to protect one patient from delayed emesis. In those patients receiving dexamethasone as standard antiemetic treatment in the delayed phase, the addition of a 5-HT 3 antagonist did not significantly improve control of delayed emesis as compared with dexamethasone monotherapy (ARR, 2.6%; 95% CI, −0.6% to 5.8%). Conclusion: Neither clinical evidence nor considerations of cost effectiveness justify using 5-HT 3 antagonists beyond 24 hours after chemotherapy for prevention of delayed emesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Grunberg, S. M., Deuson, R. R., Mavros, P., Geling, O., Hansen, M., Cruciani, G., Daniele, B., De Pouvourville, G., Rubenstein, E. B., & Daugaard, G. (2004) · Cancer · doi:10.1002/cncr.20230 · Cited by 470
Self-citationKris, M. G., Gralla, R. J., Tyson, L. B., Clark, R. A., Cirrincione, C., & Groshen, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.1.108 · Cited by 236
Ioannidis, J. P. A., Hesketh, P. J., & Lau, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3409 · Cited by 223
The Italian Group for Antiemetic Research (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422102 · Cited by 192
(1998) · Annals of Oncology · doi:10.1023/a:1008471812316 · Cited by 185
Nausea and Vomiting Remain a Significant Clinical Problem
Roscoe, J. A., Morrow, G. R., Hickok, J. T., & Stern, R. M. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00159-7 · Cited by 136
Kaizer, L., Warr, D. G., Hoskins, P. J., Latreille, J., Lofters, W., Yau, J., Palmer, M. K., Zee, B. C.-Y., Levy, M., & Pater, J. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1050 · Cited by 115
Metadata
- Authors
- Geling, O., & Eichler, H.-G.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-20
- Volume
- 23
- Issue
- 6
- Pages
- 1289-1294
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153119854
- Cited by
- 264
- References
- 14
- FWCI
- 16.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications. https://app.cochat.ai/papers/10.1200/jco.2005.04.022
- The paper
- Geling, O., & Eichler, H.-G. (2005). Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.04.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
